Finance

Lists
TEVA:NYSE
Teva Pharmaceutical Industries Limited
41,50 US$
+0,95%
(+0,39) 1D
41,50 US$
0,00% (0,00)
After hours
Closed: 16 ოქტ, 16:00:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TEVA...
Open
41,26 US$
High
41,70 US$
Low
40,96 US$
Mkt. cap
47,57 მლრდ.
Avg. vol.
5,93 მლნ.
Volume
5,94 მლნ.
52-wk high
42,02 US$
52-wk low
18,82 US$
Beta
1,07
Shares outstanding
1,17 მლრდ.
No. of employees
32 ათ.
Open
41,26 US$
High
41,70 US$
Low
40,96 US$
Mkt. cap
47,57 მლრდ.
Avg. vol.
5,93 მლნ.
Volume
5,94 მლნ.
52-wk high
42,02 US$
52-wk low
18,82 US$
Beta
1,07
Shares outstanding
1,17 მლრდ.
No. of employees
32 ათ.
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
12 საათის წინ
Barclays raises Teva target to USD 47 for Teva stock
ad-hoc-news.de
ad-hoc-news.de
·
1 დღის წინ
JPMorgan raises target for Teva stock to USD 50.00
ad-hoc-news.de
ad-hoc-news.de
·
2 დღის წინ
Barclays keeps Buy rating for Teva stock at USD 42.00
The Guardian
The Guardian
·
2 კვირის წინ
Royal College of Nursing cuts ties with Israeli drug company
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Limited
CEOრიჩარდ ფრენსის
Employees32 ათ.
Founded13 თებ. 1944
Headquarters-
SectorPharmaceutical industry
Websiteteva.co.il
Analyst ratings
Based on 9 analysts giving stock ratings to TEVA in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for TEVA in the last 3 months.
Highest
Current 41,50 US$
50,00 US$ (+20,48%)
Average
44,00 US$ (+6,02%)
Lowest
40,00 US$ (-3,61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Buy
Initiated
45,00 US$
+8,4%
09/09/2026
Ashwani Verma
UBS
Buy
Maintained
48,00 US$
+15,7%
09/04/2026
Dennis Ding
Jefferies
Buy
Maintained
40,00 US$
-3,6%
09/03/2026
Louise Chen
Scotiabank
Buy
Maintained
40,00 US$
-3,6%
09/03/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
50,00 US$
+20,5%
09/02/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
43,00 US$
+3,6%
09/02/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
09/02/2026
David Amsellem
Piper Sandler
Buy
Reiterated
44,00 US$
+6%
08/27/2026
Glen Santangelo
Barclays
Buy
Maintained
42,00 US$
+1,2%
08/12/2026
Chris Schott
J.P. Morgan
Buy
Maintained
-
-
06/15/2026
Matthew Dellatorre
Goldman Sachs
Buy
Maintained
50,00 US$
+20,5%
04/30/2026
Les Sulewski
Truist Financial
Buy
Reiterated
45,00 US$
+8,4%
04/30/2026
Last report
29 ივლ. 2026
Fiscal period
Q2 2026
0,02 US$ / 0,11 US$
-81,46%miss
Revenue / Est. (USD)
4,14 მლრდ. / 4,03 მლრდ.
+2,79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
4,48 მლრდ.
4,71 მლრდ.
3,98 მლრდ.
4,14 მლრდ.
Cost of goods sold
2,18 მლრდ.
2,06 მლრდ.
2,01 მლრდ.
1,99 მლრდ.
Cost of revenue
2,18 მლრდ.
2,06 მლრდ.
2,01 მლრდ.
1,99 მლრდ.
Research and development expenses
256,00 მლნ.
267,00 მლნ.
222,00 მლნ.
970,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
973,00 მლნ.
1,12 მლრდ.
1,00 მლრდ.
1,03 მლრდ.
Operating expense
1,24 მლრდ.
1,37 მლრდ.
1,21 მლრდ.
1,99 მლრდ.
Total operating expenses
3,41 მლრდ.
3,43 მლრდ.
3,22 მლრდ.
3,98 მლრდ.
Operating income
1,07 მლრდ.
1,28 მლრდ.
763,00 მლნ.
167,00 მლნ.
Other non operating income
-27,00 მლნ.
-
-13,00 მლნ.
-69,00 მლნ.
EBT including unusual items
648,00 მლნ.
90,00 მლნ.
436,00 მლნ.
-455,00 მლნ.
EBT excluding unusual items
832,00 მლნ.
1,08 მლრდ.
547,00 მლნ.
-57,00 მლნ.
Income tax expense
214,00 მლნ.
-390,00 მლნ.
67,00 მლნ.
121,00 მლნ.
Effective tax rate
33,02%
-433,33%
15,37%
-26,59%
Other operating expenses
9,00 მლნ.
-17,00 მლნ.
-14,00 მლნ.
-18,00 მლნ.
Net income
433,00 მლნ.
480,00 მლნ.
369,00 მლნ.
-576,00 მლნ.
Net profit margin
9,67%
10,19%
9,27%
-13,91%
Earnings per share
0,78
0,96
0,53
0,02
Interest and investment income
-
92,00 მლნ.
-
-
Interest expense
-205,00 მლნ.
-280,00 მლნ.
-191,00 მლნ.
-186,00 მლნ.
Net interest expenses
-205,00 მლნ.
-188,00 მლნ.
-191,00 მლნ.
-186,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
1,32 მლრდ.
1,54 მლრდ.
1,00 მლრდ.
408,00 მლნ.
Gain or loss from assets sale
-
-
-8,00 მლნ.
-12,00 მლნ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები